Member Info for BOJO2020

Not everything warrants a reaction. I always log on here in hope but often feel disheartened to see the regular faces playing tennis with a hand grenade. Old habits die hard I suppose. One-upmanship is just not appropriate or wanted here.

Hello Burble,

I thought Genmab were buying targets rather than the actual antibody as a whole which would cover all modalities? I mean I don’t know but that is what Lindy said for the first deal. If that is the case I am not sure that the entire platform would be for sale as it would not be practical for Genmab. Also I agree with ScinV. Better to wait for at least phase 1 efficacy. The all important leap from mouse model to human must be proven. This is not to say that Genmab would not buy the lot I suppose as they could sort out the details afterward. Whilst they are about they can buy Scancell for the right price!!

ATB

I do not agree that either of those posters have it in them to squash another contributor on a public forum. Lets leave the discussion here if that’s ok because people are happily minding their own business and don’t need you or I to drag them into what amounts to a fairly pointless discussion.

ATB

C11,

As far as I know there are two people on this bb that speak with authority about the science having the appropriate knowledge and experience. The rest of us are just borrowing sound bites from Lindy. Yes we are most definitely parrots! For the depth of knowledge and original insights we have we may as well be dead parrots. Now why don’t you give the, ‘poster,’ a break. There’s a pretty boy then 🙃

ATB

Yes Researcher did both offer and open market. It was clearly a token offer by the company. At least the picture is becoming clearer to those that are not blinded by doom or whose view is distorted by those rose tinted spectacular spectacles. This is close to being a real investment. Could move quickly now raise done

Suggesting that GGP up 2.5p but has a long way to go. A suggestion to the uninformed

This suggestion made on another forum for a stock that just multi bagged.

Always good to remember how supply chains works. GGP are NOT dependent on those higher up. The chain DEPENDS on us as we are at the top; a producer.

Sorry about the capital letters. I do not usually shout!

Cleaner thanks,

this feels like a significant moment in the evolution of targeted cancer therapy. we might be witnessing the emergence of a new class of cancer therapeutics.

That makes the Genmab deals seem cheap! However they have taken the time and trouble when apparently nobody else has. This is exactly the kind of validation not to mention inferred anecdotal validation the platform needs. Now competing bidders please. Roll up, roll up, when they are gone they are gone.

PWF

Why do you believe in not correcting misinformation? Ok most of us do not have the specific depth of knowledge to do so. But those that do have such knowledge should step up and correct misinformation with good grace and manners. Otherwise the misinformation fills the vacuum.

Dipp

You’re 15:31.

You are clearly intelligent and well researched. Why oh why you try and belittle people on this forum is beyond me. There is no need to wrap your message in a house brick, unless you are a yob?

Yes Dragon on Ii. Although I had to call up as the online transaction would not go through. Ordered 30k shares.

It did say the deadline was 3pm today mind

Hi Berm,

I wonder if subcutaneous administered drugs work better. Particularly how much of a role does this play in the excellent Scancell results. This may well be a question for SCIB when scrutinsed following results. In any case SCLP will need to prove how they acheive results and how much it is down to the asset itself. Appreciate there is a lot to unpick with this but these things must be clearly understood in time.

Ruck v.good post. Obviously Scancell are now a clinical company as opposed to pre clinical so all that money raised has indeed been well spent. @Cars made a point maybe yesterday that something along the lines that if the only thing that is missing is cash (all other things being excellent) then what’s the problem with a raise. That jolted me out of my temporary stupor. I think 13 to 15 is very realistic in the short term. However this time next year we will be in the same cash boat. All be it with further excellent results.

So I added a big chunk today

Jam,

I stopped putting fresh cash into my portfolio about 12 months ago. Since then it has grown significantly as I pay close attention to profits! So much so that I have withdrawn cash and it is still growing. Until today haha!

XV,

I sold a third between 14 to 19p as I reconciled the move from 10p to 19p was 100% ish and likely just heavy buying. Did not like the Genmab deal announced today as it fell very short of filling the obvious imminent funding gap. I seriously considered selling another third today but sold just 10% to see what happened over the next few days! Ouch!

This appears to be stuck in a funding circle. Management should have pumped the price a bit before raise. I know there are many on here that buy every month to build for the future. They will be hurting as the average is way over 10.5p

Don’t know what happened today with SP reaction and I see little point guessing but these results warrant patience imo.

I am sure that Scancell are totally focused on trial protocol and endpoints. As they should be. Eejits in the White House come and go. Solid facts and data aint going anywhere and will remain in 4 or 8 years time.

Well yes. At least Nasdaq exhists! The idea of Pisces is to direct investment into the UK junior sector so that companies that have real potential are prioritised. They need to do something about the junior markets. Try and imagine how many billions are wiped from peoples ISA's and SIPPS each year. That money is lost and will not be spent on new clothes, cars, houses etc. How many cars etc could you all have bought if your AIM investments were not tanking...I look at it as two new Merc Sprinter vans for me in the last 4 years.

On the Mansion House Speeches by the Chancellor and the G.B.E last evening?

Heard mention of the Pisces market with a mere mention from Chancellor. Would does this mean for AIM. Is it a half way house between AIM and the FTSE markets? Could be interesting for companies like Scancell that prove to have true potential.

Non political thoughts please!

First consideration would be to use the best vaccine based on clinical data.

Secondary considerations would be cost, ease of manufacturing, ease of use, storage ect etc

Also who is paying/buying? If it is NHS or US insurance footing the bill then there is a process but I am guessing they will not compromise on quality. Maybe in developing countries if they cannot afford they may be able to cut a special deal or used as a demonstrator? If the second best vaccine is cheaper but nearly as effective as Ruck Rover says then I can see a market for both. Remember, even when authorsied, we do not know the long term effects and benefits of drugs. That will take decades.

Also remember that any of these vaccines such as Modi 1 or personalised vaccines if clinically successful would be world firsts... They are not going to be cheap.

Re: the professors comments surrounding costs of off the shelf. Looks like raw material costs to me